Tenax Therapeutics (TENX) Registration Filing summary

Company overview and business model

• Clinical-stage pharmaceutical company focused on developing novel cardiopulmonary therapies using a clinician-driven approach targeting disease pathophysiology.

• Prioritizes development of levosimendan and imatinib, both previously approved for other indications, for use in pulmonary hypertension and related conditions.

• Leverages collaborations with key opinion leaders, research institutions, and strategic partners to advance clinical programs and expand therapeutic applications.

• Emphasizes intellectual property expansion, formulation improvements, and licensing or co-development arrangements to accelerate product development and commercialization.

Financial performance and metrics

• Raised approximately $100 million in August 2024 and $25 million in March 2025 through private placements to fund clinical development.

• Proceeds are allocated to advancing Phase 3 trials for oral levosimendan and supporting regulatory submissions.

Use of proceeds and capital allocation

• Net proceeds from recent private placements are intended to complete ongoing Phase 3 studies and initiate additional global trials for levosimendan.

• Any nominal proceeds from warrant exercises will be allocated to working capital.

• No proceeds from the resale of shares by selling stockholders; company covers registration and related expenses.